New bladder cancer cocktail aims to spare patients from surgery

NCT ID NCT06829823

Not yet recruiting Disease control Sponsor: ImmunityBio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether a drug called N-803, combined with either BCG or gemcitabine, can treat intermediate-risk bladder cancer without needing surgery. About 20 adults with low-grade papillary tumors will receive the drugs directly into the bladder. The main goal is to see if the cancer disappears by 3 or 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: N-803 (a drug that boosts the immune system) combined with either BCG (a weakened bacteria used in immunotherapy) or gemcitabine (a chemotherapy drug)
What this could lead to: If successful, this could offer a way to treat intermediate-risk bladder cancer without surgery, using a combination of immune-boosting and standard therapies.
What could go wrong: This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The treatments may cause side effects or fail to control the cancer long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTERMEDIATE-RISK NON-MUSCLE INVASIVE PAPILLARY BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.